A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: Results from the AIBL study

Molecular Psychiatry

Volumn 19, Issue 4, 2014, Pages 519-526

  Burnham, S C ^a   Faux, N G ^b   Wilson, W ^a   Laws, S M ^c,d   Ames, D ^b,e   Bedo, J ^a   Bush, A I ^b   Doecke, J D ^a   Ellis, K A ^b   Head, R ^a   Jones, G ^b,f   Kiiveri, H ^a   Martins, R N ^c,d   Rembach, A ^b   Rowe, C C ^b,f   Salvado, O ^a   Macaulay, S L ^a   Masters, C L ^b   Villemagne, V L ^f  

^a CSIRO   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^f AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta; Blood biomarkers

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; IMMUNOGLOBULIN M; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PANCREAS POLYPEPTIDE; PITTSBURGH COMPOUND B; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; CHEMOKINE CCL3; COHORT STUDIES; CULLIN PROTEINS; FEMALE; HUMANS; INTERLEUKIN-17; MALE; NEOCORTEX; PANCREATIC POLYPEPTIDE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; ROC CURVE; THIAZOLES;

EID: 84897108729     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.40     Document Type: Article

References (50)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical-Diagnosis of Alzheimers-Disease-Report of the NINCDS-ADRDA Work Group under the Auspices of Department-of-Health-and-Human-Services Task-Force on Alzheimers-Disease. Neurology 1984; 34: 939-944
2. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 2006; 97: 1700-1725
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292
4. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-368
5. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283
6. Blennow K. CSF biomarkers in Alzheimer's disease-use in clinical diagnosis and to monitor treatment effects. Eur Neuropsychopharmacol 2010; 20: S159-S159
7. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672-687
8. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246
9. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment-Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
10. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-105
11. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001; 304: 102-106
12. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008; 70: 1664-1671
13. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B et al. Plasma Amyloidbeta as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. J Alzheimers Dis 2010; 20: 1233-1242
14. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA et al. Plasma apolipoprotein E and Alzheimer disease risk The AIBL study of aging. Neurology 2011; 76: 1091-1098
15. Hixson JE, Vernier DT. Restriction isotyping of human Apolipoprotein-E by gene amplification and cleavage with HHAI. J Lipid Res 1990; 31: 545-548
16. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 2011; 20: 40-49
17. Jagust WJ, Bandy D, Chen KW, Foster NL, Landau SM, Mathis CA et al. The alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221-229
18. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labelling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Statistic Soc B 1995; 57: 289-300
20. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD et al. Biological markers for therapeutic trials in Alzheimer's disease-proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003; 24: 521-536
21. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH et al. (11) PIB in a nondemented population-potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452
22. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844
23. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517
24. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S et al. A beta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-1697
25. Blacker D, Haines JL, Rodes L, Terwedow H, Go RCP, Harrell LE et al. ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative. Neurology 1997; 48: 139-147
26. Doecke JD, Laws SM, Faux N, Wilson W, Burnham SC, Lam C-P et al. Blood-based protein biomarkers for diagnosis of alzheimer disease. Arch Neurol 2012; 69: 1-8
27. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M et al. A blood-based screening tool for alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS ONE 2011; 6: e28092
28. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann F, Shera D et al. Plasma biomarkers associated with the apolipoprotein e genotype and alzheimer disease. Arch Neurol 2012 1-8
29. Johns CE, Newton JL, Westley BR, May FEB. Human pancreatic polypeptide has a marked diurnal rhythm that is affected by ageing and is associated with the gastric TFF2 circadian rhythm. Peptides 2006; 27: 1341-1348
30. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Holst JJ, Hilsted L et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 2005; 90: 5241-5246
31. Druce MR, Small CJ, Bloom SR. Minireview: gut peptides regulating satiety. Endocrinology 2004; 145: 2660-2665
32. Hallgren R, Lundqvist G. Elevated levels of circulating pancreatic-polypeptide in inflammatory and infectious disorders. Regul Pept 1980; 1: 159-167
33. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signalling proteins. Nat Med 2007; 13: 1359-1362
34. OMIM. Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine. Johns Hopkins University: Baltimore, MD, USA, 2012
35. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX et al. Plasma beta-amyloid and cognitive decline. Arch Neurol 2010; 67: 1485-1490
36. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men. Arch Neurol 2008; 65: 256-263
37. Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M et al. Amyloidbeta peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J Alzheimers Dis 2010; 21: 1263-1269
38. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N et al. Plasma A beta 40 and A beta 42 and Alzheimer's disease-relation to age, mortality, and risk. Neurology 2003; 61: 1185-1190
39. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46: 412-416
40. Rembach A, Faux N, Watt A, Pertile KK, Rumble RL, Trounson BO et al. Changes in plasma b-amyloid in a longitudinal study of ageing and Alzheimer's disease. Alzheimers Dement 2013; pii: S1552-5260(13)00009-5; doi:10. 1016/j. jalz. 2012. 12. 006 (e-pub ahead of print)
41. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW et al. Factors affecting A beta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011; 122: 401-413
42. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR et al. Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 2010; 30: 6315-6322
43. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain Abeta amyloid. Alzheimers Dement 2011; 7: 133-141
44. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T et al. A serum proteinbased algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67: 1077-1081
45. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127
46. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr. CR, Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269
47. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279
48. Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K et al. Beta-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127
49. Morris JC, Roe CM, Mintun MA. Preclinical Alzheimer's disease: relationship with brain/cognitive reserve. Gerontologist 2009; 49: 145-145
50. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.